PE20181143A1 - Compuestos para uso en aplicaciones antibacterianas - Google Patents

Compuestos para uso en aplicaciones antibacterianas

Info

Publication number
PE20181143A1
PE20181143A1 PE2018000236A PE2018000236A PE20181143A1 PE 20181143 A1 PE20181143 A1 PE 20181143A1 PE 2018000236 A PE2018000236 A PE 2018000236A PE 2018000236 A PE2018000236 A PE 2018000236A PE 20181143 A1 PE20181143 A1 PE 20181143A1
Authority
PE
Peru
Prior art keywords
compounds
amino
alkyl
methyl
infections
Prior art date
Application number
PE2018000236A
Other languages
English (en)
Inventor
Haifeng Cui
Alan Hennessy
Qi Jin
Timothy James Miles
Stephen Frederick Moss
Neil David Pearson
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PE20181143A1 publication Critical patent/PE20181143A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Se refiere a compuestos de formula general (I), donde Z1 es C o N; Z2 es CH o N, donde si Z1 es N, R1 no esta presente; R1, R2 y R3 son seleccionados independientemente de H o alquilo (C1-C6); X1 es seleccionado de O o S; L1 es seleccionado de un enlace -O-, alquilo (C1-C6), -C(=O), entre otros; X es arilo (C5-C14), heteroarilo (C2-C9), cicloalquilo (C3-C12), entre otros; L2 es seleccionado de un enlace, -O-, alquilo (C1-C6), -C(=O), entre otros; Y es un heteroarilo (C5-C14) que contiene al menos un heteroatomo seleccionado independientemente de O, N y S donde dicho (C5-C14), esta opcionalmente sustituido con al menos un grupo seleccionado de (alquilo C1-C6), (alcoxi C1-C6), halogeno, entre otros; m, n, p son un numero entero que varia de 0 a 8; q es un numero entero que varia de 0 a 8. o una sal farmaceuticamente aceptable del mismo. Tambien se refiere a sales farmaceuticamente aceptables, solvatos o N-oxidos que comprenden los compuestos de formula (I). Son compuesto preferidos: 6-((((1R,4R)-4(((6-fluoro-3-metoxiquinoxalin-5-il)metil)amino)ciclohexil)amino)metil)-2H-pirazino[2,3-b][1,4]oxazin-3(4H)-ona, 6-((((1R,3S,4R)-4(((6-fluoro-3-metoxiquinoxalin-5-il)metil)amino)hidrociclohexil)amino)metil)-2H-pirazino[2,3-b][1,4]oxazin-3(4H)-ona, entre otros. Dichos compuestos son utiles para el tratamiento de infecciones bacterianas causadas por organismos Gram-negativos tales como Haemophilus influenza, Moraxella catarrhalis, Acinetobacter baumanii, entre otros, organismos Gram-positivos tales como Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, entre otros, infecciones del tracto respiratorio superior y/o inferior, infecciones de la piel y los tejidos blandos y/o infecciones del tracto urinario
PE2018000236A 2015-08-16 2016-08-15 Compuestos para uso en aplicaciones antibacterianas PE20181143A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562205732P 2015-08-16 2015-08-16
US201662308928P 2016-03-16 2016-03-16

Publications (1)

Publication Number Publication Date
PE20181143A1 true PE20181143A1 (es) 2018-07-17

Family

ID=57218948

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000236A PE20181143A1 (es) 2015-08-16 2016-08-15 Compuestos para uso en aplicaciones antibacterianas

Country Status (22)

Country Link
US (2) US10364254B2 (es)
EP (1) EP3334739A2 (es)
JP (1) JP6757402B2 (es)
KR (1) KR20180038046A (es)
CN (1) CN108137616B (es)
AU (2) AU2016307969C1 (es)
CA (1) CA2995715A1 (es)
CL (1) CL2018000403A1 (es)
CO (1) CO2018002204A2 (es)
CR (1) CR20180111A (es)
DO (1) DOP2018000049A (es)
EA (1) EA033314B1 (es)
HK (1) HK1248680A1 (es)
IL (1) IL257265B (es)
MA (1) MA42621A (es)
MX (1) MX2018002033A (es)
PE (1) PE20181143A1 (es)
PH (1) PH12018500358A1 (es)
TW (1) TW201722965A (es)
UY (1) UY36851A (es)
WO (1) WO2017029602A2 (es)
ZA (1) ZA201800722B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722965A (zh) * 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 用於抗菌應用之化合物
WO2019180634A1 (en) 2018-03-23 2019-09-26 Glaxosmithkline Intellectual Property Development Limited Synthesis of oxazinone-containing bicyclic aromatic and heteroaromatic aldehydes
TW202116782A (zh) 2019-07-16 2021-05-01 瑞士商愛杜西亞製藥有限公司 喹啉酮衍生物
CN111269247B (zh) * 2020-03-04 2020-11-24 河南科技大学第一附属医院 具有抑制大肠杆菌作用的噻嗪酮药物分子的制备方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (es) * 1969-10-13 1971-09-23 Eisai Co Ltd
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
CA1224992A (en) 1982-10-08 1987-08-04 Robert E. Newell Device for administering medicament to patients
GR861995B (en) 1985-07-30 1986-11-04 Glaxo Group Ltd Devices for administering medicaments to patients
JPH0733379B2 (ja) * 1986-06-27 1995-04-12 エーザイ株式会社 光学活性α−トコフエロ−ルの製造方法
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
DE60025048D1 (de) 2000-07-21 2006-01-26 Ljudmila Petrovna Maljuk Teller für stehempfänge
EP1305308B1 (en) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
WO2002050036A1 (en) 2000-12-21 2002-06-27 Ciba Speciality Chemicals Holding Inc. Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
JP4445753B2 (ja) 2002-01-29 2010-04-07 グラクソ グループ リミテッド アミノピペリジン誘導体
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
AR040335A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
CN100427487C (zh) 2002-06-27 2008-10-22 弗·哈夫曼·拉罗切有限公司 嘌呤衍生物的合成
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
ATE463494T1 (de) 2002-10-10 2010-04-15 Morphochem Ag Komb Chemie Neue verbindungen mit antibakterieller aktivität
WO2004041210A2 (en) 2002-11-05 2004-05-21 Smithkline Beecham Corporation Antibacterial agents
WO2004096982A2 (en) 2002-11-05 2004-11-11 Smithkline Beecham Corporation Antibacterial agents
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
CA2549341C (en) 2003-12-19 2014-06-10 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
WO2006002047A2 (en) 2004-06-15 2006-01-05 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1773831A1 (en) 2004-07-08 2007-04-18 Glaxo Group Limited Antibacterial agents
JP2008505926A (ja) * 2004-07-09 2008-02-28 グラクソ　グループ　リミテッド 抗細菌剤
EP1773343A4 (en) 2004-07-13 2009-05-13 Glaxo Group Ltd ANTIBACTERIAL AGENTS
EP1778688A1 (en) 2004-07-22 2007-05-02 Glaxo Group Limited Antibacterial agents
EP1781669B1 (en) 2004-08-02 2010-10-13 Glaxo Group Limited Antibacterial agents
JP2008509222A (ja) 2004-08-09 2008-03-27 グラクソ グループ リミテッド 抗菌剤
DE102004041163A1 (de) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2006032466A2 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
ES2343127T3 (es) 2004-10-05 2010-07-23 Actelion Pharmaceuticals Ltd. Nuevos antibioticos de piperidina.
WO2006046552A1 (ja) 2004-10-27 2006-05-04 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
WO2006081264A1 (en) * 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
RU2007147413A (ru) 2005-05-24 2009-06-27 Астразенека Аб (Se) Аминопиперидинхинолины и их азаизостерические аналоги с антибактериальной активностью
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
JP5398984B2 (ja) 2005-06-24 2014-01-29 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
EP2537657A3 (en) 2005-08-09 2016-05-04 The University of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
WO2007081876A2 (en) 2006-01-04 2007-07-19 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
EP1987040B1 (en) * 2006-02-15 2010-11-10 Actelion Pharmaceuticals Ltd. Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
BRPI0712163A2 (pt) 2006-05-26 2012-03-13 Toyama Chemical Co., Ltd. composto, e, agente antimicrobiano
EP1992628A1 (en) * 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
WO2008013952A2 (en) 2006-07-27 2008-01-31 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
CL2007003693A1 (es) 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
GB0707704D0 (en) * 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
WO2009024342A2 (en) * 2007-08-23 2009-02-26 Syngenta Participations Ag Novel microbiocides
CN103660089B (zh) 2007-10-12 2017-04-12 流体科技公司 用于生产颗粒和图案化膜的系统和方法
JP5620636B2 (ja) 2007-11-26 2014-11-05 富山化学工業株式会社 新規な複素環化合物またはその塩を含有する抗菌剤
CN104151316B (zh) * 2008-10-07 2016-06-15 埃科特莱茵药品有限公司 三环噁唑烷酮抗生素化合物
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
TW201022279A (en) * 2008-11-14 2010-06-16 Astrazeneca Ab Chemical compounds
KR101880582B1 (ko) 2008-12-05 2018-07-20 리퀴디아 테크놀로지스 인코포레이티드 패턴 재료 제조 방법
SI2376497T1 (sl) * 2008-12-12 2014-01-31 Actelion Pharmaceuticals Ltd. Derivati 5-amino-2-(1-hidroksi-etil)-tetrahidropirana
JP5656996B2 (ja) 2009-07-13 2015-01-21 ザ ユニバーシティ オブ ノース キャロライナ アット チャペル ヒル 工学的に作製されたエアロゾル粒子、およびそれに関連した方法
TW201209056A (en) * 2010-05-25 2012-03-01 Taisho Pharmaceutical Co Ltd Novel heterocyclic compound or salt thereof
EP2723737A1 (en) * 2011-06-27 2014-04-30 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
WO2013080156A1 (en) * 2011-11-30 2013-06-06 Actelion Pharmaceuticals Ltd 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
ES2640482T3 (es) 2013-04-16 2017-11-03 Idorsia Pharmaceuticals Ltd Derivados biaromáticos antibacterianos
TW201722965A (zh) * 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 用於抗菌應用之化合物

Also Published As

Publication number Publication date
WO2017029602A3 (en) 2017-04-13
AU2016307969C1 (en) 2019-09-05
JP2018523675A (ja) 2018-08-23
US20190270755A1 (en) 2019-09-05
CA2995715A1 (en) 2017-02-23
US10683307B2 (en) 2020-06-16
PH12018500358A1 (en) 2018-09-03
CN108137616A (zh) 2018-06-08
IL257265A (en) 2018-03-29
CR20180111A (es) 2018-04-12
US20190031680A1 (en) 2019-01-31
AU2016307969B2 (en) 2019-02-14
AU2019200226B2 (en) 2020-01-23
CN108137616B (zh) 2020-06-26
KR20180038046A (ko) 2018-04-13
MX2018002033A (es) 2018-06-15
AU2016307969A1 (en) 2018-03-08
IL257265B (en) 2020-07-30
US10364254B2 (en) 2019-07-30
CL2018000403A1 (es) 2018-07-06
HK1248680A1 (zh) 2018-10-19
ZA201800722B (en) 2019-07-31
AU2019200226A1 (en) 2019-01-31
UY36851A (es) 2017-03-31
EA201890412A1 (ru) 2018-08-31
TW201722965A (zh) 2017-07-01
JP6757402B2 (ja) 2020-09-16
WO2017029602A2 (en) 2017-02-23
MA42621A (fr) 2018-06-20
DOP2018000049A (es) 2018-03-30
EP3334739A2 (en) 2018-06-20
EA033314B1 (ru) 2019-09-30
CO2018002204A2 (es) 2018-06-20

Similar Documents

Publication Publication Date Title
PE20181143A1 (es) Compuestos para uso en aplicaciones antibacterianas
CL2018000292A1 (es) Compuestos farmacéuticos
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
AR100160A1 (es) 1H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS Y PIRAZOLO[3,4-c]PIRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEÍNAS BET
EA201490634A1 (ru) Производные полимиксина
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
WO2015044886A3 (en) Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
IN2014DN03063A (es)
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
PE20201256A1 (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas
CO2019002624A2 (es) Compuestos antibióticos
NZ704627A (en) Spirocyclic isoxazoline parasiticidal combinations
WO2016100578A3 (en) Antimicrobial polymyxins for treatment of bacterial infections
AR092307A1 (es) Derivados de manosa para el tratamiento de infecciones bacterianas
AR077141A1 (es) Derivados de 4-aminopicolatos sustituidos, procesos de preparacion y composiciones herbicidas que lo comprenden
CR20190236A (es) Compuestos terapéuticos y métodos para utilizarlos
AR110769A1 (es) Compuestos de 1h-indazol, composición farmacéutica que lo comprende y su uso para fabricar un medicamento
AR114309A1 (es) Compuestos antibacterianos, composiciones de los mismos, y métodos que utilizan los mismos
PE20221006A1 (es) Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
CO2022010084A2 (es) Compuestos novedosos y sus usos